Clinical Trial Update: Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating subcutaneous rilonacept for non-dialysis-dependent chronic kidney disease with anemia was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• Rilonacept (rilonacept)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Chronic Kidney Disease, Anemia | Phase 2 | Status: WITHDRAWN